Kaketsuken Scandal Prompting Japan Regulatory Tightening
This article was originally published in PharmAsia News
Executive Summary
Major Japanese vaccines and blood products producer Kaketsuken is sinking ever deeper into a major manufacturing and data falsification scandal it has emerged stretches back more than 40 years, prompting discussion of official administrative sanctions and possibly criminal proceedings and moves to strengthen regulatory oversight.
You may also be interested in...
Lost In Translation? Japan’s GMP Compliance Dilemma
As Japan tightens regulations for good manufacturing practice, some members of the domestic pharma industry, including one inspector, are recognizing the need for official translations for foreign companies, which the ministry denied a year ago and continue to present challenges.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.